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Abstract
Importance—Long-acting injectable (LAI) antipsychotics are used to reduce medication non-
adherence and subsequent relapse in schizophrenia-spectrum disorders. The relative effectiveness
of LAI versions of second-generation (atypical) and older antipsychotics has not been assessed.
Objective—To compare the effectiveness of the second-generation LAI antipsychotic
paliperidone palmitate (PP) to the older LAI antipsychotic haloperidol decanoate (HD).
Design, Setting, and Participants—Multisite, double-blind, randomized clinical trial
conducted at 22 clinical research sites in the U.S. The 311 randomized patients (PP=157,
HD=154) were adults diagnosed with schizophrenia or schizoaffective disorder who were
clinically assessed to be at risk of relapse and likely to benefit from a LAI antipsychotic.
Interventions—Intramuscular injections of HD 25–200 mg or PP 39–234 mg every month for
up to 24 months.
Main Outcome Measures—Efficacy failure, which reflected inadequate control of
psychopathology by the study medication, as determined by a blinded adjudication committee.
Key secondary outcomes were common adverse effects of antipsychotic medications.
Results—There was no statistically significant difference in the rate of efficacy failure for PP
compared to HD (adjusted hazard ratio 0.98, 95% confidence interval [CI] 0.65–1.47). On
average, patients on PP gained and those on HD lost weight; after six months the least squares
mean weight change on PP was +2.17 kg (1.25 to 3.09) and on HD was −0.96 kg (−1.88 to −0.04).
Patients taking PP had significantly greater increases in serum prolactin (men 34.56 µg/L (29.75 to
39.37) vs. 15.41 (10.73 to 20.08), p<0.001; women 75.19 (63.03 to 87.36) vs. 26.84 (13.29 to
40.40), p<0.001). Patients taking HD had significantly larger increases in global ratings of
akathisia (0.73 [0.59 to 0.87] vs. 0.45 [0.31 to 0.59], p=0.006).
Conclusions and Relevance—Among adults with schizophrenia or schizoaffective disorder,
treatment with paliperidone palmitate compared with haloperidol decanoate did not result in a
statistically significant difference in efficacy failure, but was associated with more weight gain
and greater increases in serum prolactin, whereas haloperidol was associated with more akathisia.
However, based on the 95% confidence limits, a clinically meaningful difference in efficacy
failure between treatments cannot be ruled out.
Trial Registration—clinicaltrials.gov identifier NCT01136772
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Long-acting injectable (LAI) antipsychotic medications are prescribed to reduce non-
adherence and relapse in people diagnosed with a schizophrenia-spectrum disorder. LAI
versions of older or “typical” antipsychotics have been available for decades but their use
has been limited in part due to their propensity to cause extrapyramidal side effects (EPS),
including tardive dyskinesia. Beginning in 1989, oral forms of newer “atypical”
antipsychotic medications considered to entail lower risk of EPS were introduced. Due to
rapid acceptance of the newer oral antipsychotics, LAI versions of these medications were
anticipated to gain widespread use. The first of these, risperidone microspheres, was
introduced in 2003. Risperidone microspheres, however, must be refrigerated before use,
reconstituted with a diluent provided by the manufacturer, and administered bi-weekly. In
2009, a long-acting version of risperidone’s active metabolite, paliperidone, was brought to
market. Paliperidone palmitate can be administered monthly and does not require
refrigeration or reconstitution. Because of these logistical advantages, paliperidone palmitate
was considered to be an important advance in LAI antipsychotics, although its high
acquisition cost made its role uncertain.1
In recent years head-to-head trials and meta-analyses have called into question the
advantages of the atypical antipsychotic medications over typical antipsychotics.2–5 The
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
showed that when an older drug, perphenazine, was used at moderate doses that several
newer ones were not superior in safety or effectiveness.3 A recent secondary analysis
provided evidence that perphenazine is non-inferior to olanzapine, quetiapine, and
risperidone with respect to symptom scores.6 Moreover, some newer antipsychotics were
shown to cause significant weight gain and to be associated with dyslipidemias and diabetes
mellitus.7,8
This investigation compared the effects of LAI paliperidone palmitate (PP) and haloperidol
decanoate (HD), an older, widely used LAI antipsychotic. Based on an earlier comparison of
oral risperidone to oral haloperidol,9 we hypothesized that PP would be associated with
lower rates of efficacy failure and EPS than HD, but that HD would cause less weight gain
and less increase in serum prolactin levels.
Method
Study setting and design
A Comparison of Long-acting Injectable Medications for Schizophrenia (ACLAIMS) was a
multisite, parallel-group, double-blinded randomized clinical trial. The study was conducted
at 22 U.S. clinical sites affiliated with the National Institute of Mental Health-supported
Schizophrenia Trials Network. Each site obtained institutional review board approval to
conduct the study.
Patients
Patients were adults aged 18–65 with a diagnosis of schizophrenia or schizoaffective
disorder as defined by DSM-IV-TR criteria and confirmed by the Structured Clinical
Interview for DSM-IV (SCID). Patients were eligible if judged by their clinician and study
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psychiatrist as likely to benefit from treatment with PP or HD and to be at risk of efficacy
failure based on a history of medication non-compliance and/or significant substance abuse.
All patients demonstrated adequate decisional capacity to participate and provided written
informed consent.
Patients with the following characteristics were excluded: currently stable and doing well on
an antipsychotic regimen; not expected to benefit from the study medications due to past
experience with risperidone, haloperidol, or paliperidone due to adverse effects or no
improvement of severe symptoms in spite of an adequate treatment trial of at least 6 weeks
duration; moderate or severe tardive dyskinesia; presence of any medical condition that
might preclude safe completion of the study; or intellectual disability. Women who were
pregnant or breastfeeding were also excluded.
Patients attended a screening visit. If potentially eligible, a baseline visit was scheduled
within 21 days. If determined eligible at the baseline visit, patients were then randomized on
a 1:1 basis to PP or HD using an internet-based system.
Interventions
A total of 353 patients enrolled for screening; 311 were eligible and randomized to study
treatment. Study treatments were long-acting injectable PP supplied in dosages of 39 mg, 78
mg, 117 mg, 156 mg and 234 mg; and HD supplied in vials of 50 mg/ml or 100 mg/ml for
injection. Each participant received a blinded trial of the oral version of the assigned
medication prior to receiving an injection. In the case of PP the oral trial was with
risperidone in accordance with the product label. The oral trial lasted from 4–7 days, with
each patient recommended to receive 2 mg of either haloperidol or risperidone on days 1 and
2 and 4 mg thereafter. Haloperidol 2 mg and risperidone 2mg were supplied in identical-
appearing capsules. Oral benztropine 1 mg was supplied to treat EPS if needed. Patients who
demonstrated allergy, EPS not relieved by benztropine, or other intolerability to the oral trial
were dropped from the trial. Seventeen randomized patients never received the assigned LAI
antipsychotic; only two of these were due to intolerability to the oral medication trial. The
first injection was given 4–7 days after the baseline visit. Subsequent visits were at weeks 1,
2, 4, 6, 8, 10, and 12, then monthly (i.e., every four weeks) for up to 24 months.
Study physicians and all other personnel were blinded to treatment condition. Study
physicians wrote orders for both of the potential LAI antipsychotic medications, for
example: “If HD, administer 50 mg IM; If PP, administer 117 mg IM.” Each patient was
then injected with only the randomly assigned drug. A clinician not otherwise involved in
the trial administered the injection and concealed the identity of the medication from the
patient and study personnel.
The loading strategy schedule described in the PP prescribing information was
recommended for both drugs. The recommended starting dose of PP was 234 mg IM on day
1 followed on day 8 with 156 mg IM. The recommended standard monthly dose of PP was
117 mg. The recommended starting dose of HD was 50 mg IM on day 1 followed on day 8
with 50 mg IM. On day 28 the recommended dose of HD was 75 mg IM to be followed on
day 56 and on subsequent monthly visits with 50 mg IM. The first two injections were given
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in the deltoid (day 1 and day 8). Subsequent monthly injections were given in the deltoid or
gluteal muscle. The recommended injection schedules were adjusted according to the
clinical situation. For the first 8 weeks clinicians were allowed to supplement the LAI with
any oral antipsychotic as needed.
Investigators were required to consult with the project’s safety officer, who was a physician
blinded to treatment assignment, if there was a desire to continue the patient on study
treatment when the following criteria were met: new onset diabetes mellitus, weight gain ≥
15 pounds, increase in low-density lipoprotein (LDL) cholesterol ≥ 20 mg/dl, worsening
tardive dyskinesia, hospitalization, clinical worsening as indicated by the Clinical Global
Impressions scale, or any serious adverse event. After the safety officer reviewed the case,
study medication was continued if the clinician considered it in the best interest of the
patient to continue and the patient and safety officer concurred.
Outcome Measures
The primary outcome was efficacy failure, which reflected inadequate control of the
psychopathology of schizophrenia or schizoaffective disorder. Efficacy failure was
determined for each study participant by an Outcome Adjudication Committee (OAC)
consisting of three research psychiatrists who were blind to treatment assignment and not
otherwise involved in the study. A majority vote of the committee determined whether and
when a participant experienced efficacy failure. The criteria considered for efficacy failure
included psychiatric hospitalization; a need for crisis stabilization; a clinically meaningful
increase in frequency of outpatient visits; a clinician’s decision that oral antipsychotic could
not be discontinued within 8 weeks after starting the LAI; a clinician’s decision to
discontinue the assigned LAI due to inadequate therapeutic benefit; or, for patients
successfully transitioned to study LAI within 8 weeks, ongoing or repeated need for
adjunctive oral antipsychotic medication.
Secondary outcome measures included change in weight from baseline and worst changes in
fasting blood glucose, glycosolated hemoglobin, cholesterol, triglycerides and prolactin. The
worst changes (e.g., highest recorded level of triglycerides, lowest recorded levels of HDL)
were used for these laboratory-measured outcomes because interventions to treat
abnormalities were allowed. Other important secondary outcomes included measures of
abnormal involuntary movements, akathisia, Parkinsonism, and sexual functioning. Weight
and measures of neurologic side effects were obtained at all study visits. Laboratory blood
tests were obtained at screening, months 3 and 6, and then every 6 months. Patients were
systematically queried about 12 adverse effects commonly associated with antipsychotic
medications at each visit. Symptoms were measured using the Positive and Negative
Syndrome Scale (PANSS) at baseline, month 1, and then every three months.
Statistical methods
The primary analysis was conducted among the modified intent-to-treat (mITT) population,
which consisted of all patients who received at least one injection and at least one post-
baseline assessment. The Kaplan-Meier (KM) method was used to estimate the proportion
without efficacy failure by time since first injection and a site stratified (two-sided) log-rank
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test for the primary comparison of time until efficacy failure. In the primary analysis, we
censored patients 90 days after their last injection to account for the time most likely
affected by the long-acting study medications. Planned supporting and sensitivity analyses
included 1) estimating the hazard ratio (and 95% CI) using a Cox proportional hazards
model (controlling for baseline PANSS score and site), 2) repeating the site stratified log-
rank test without censoring 90 days after last injection, and 3) conducting an unstratified
log-rank test. We expanded the Cox model to test for site by treatment interaction and to test
whether the hazard ratio for treatment was equal across three predefined time intervals:
months 1–3, months 4–12, and months 13–24.10 We repeated the site stratified log-rank test
for one subgroup defined a priori, participants who were not in an exacerbated state (i.e., not
hospitalized) at randomization. All main effects of treatment and treatment by site
interactions for safety analyses were tested at the 2–sided α=0.05 level. For efficacy,
interactions were tested at the α=0.10 level.
Safety analyses excluded data collected more than 6 weeks after a participant’s last
injection. Mixed effect linear models (with spatial power covariance structure) were used to
compare weight change over time. Fixed effects were included for assigned treatment,
clinical site, baseline weight, time (months since first injection) and treatment by time
interaction. The proportion of patients whose weight ever increased at least 15 pounds from
baseline was compared using a Mantel-Haenszel chi-square test. ANCOVA was used for
metabolic analyses, with the worst case as the outcome and treatment, site, and baseline
value as covariates.
The same ANCOVA approach was used for comparisons of worst AIMS global score,
Barnes Akathisia Scale (BAS) global score and Simpson-Angus Extrapyramidal Scale
(SAS) score. Incidence of clinically significant scores on three different assessments (i.e.,
AIMS global score ≥2, Barnes Akathisia Scale global score ≥3, and Simpson-Angus
Extrapyramidal Scale score ≥1)11 were compared between treatment groups using Mantel-
Haenszel chi-square tests excluding patients who had a clinically significant score at
baseline. As a post hoc analysis, the proportions meeting Schooler-Kane criteria for tardive
dyskinesia (at least moderate dyskinetic movements in one body area or mild dyskinetic
movements in two body areas)12 were compared using Mantel-Haenszel chi-square tests,
excluding patients who met criteria at baseline.
For prolactin and associated adverse effects, separate analyses were planned for men and
women. The key comparisons used ANOVA to compare the highest recorded prolactin level
as the response, with treatment and site as covariates. Supporting analyses compared
incidence of associated abnormalities (e.g, gynecomastia or galactorrhea) between treatment
groups using a Mantel-Haenszel chi-square test or Barnard’s exact test (if fewer than 10
events were observed) and highest Arizona Sexual Experiences (ASEX) scale score using
ANOVA.
The original plan to randomize a total of 360 patients and follow for 2 years was modified
due to resource constraints. The recruitment period was March 2011–July 2012; follow-up
ended in July 2013. Ultimately 311 individuals were randomized. The earliest enrollees
were followed for up to 24 months and the last enrollees for up to 12 months. The planned
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sample size was expected to provide at least 80% power to detect a difference in survival
curves (two-sided log rank test, alpha=0.05) assuming efficacy failure rates of 0.56 and 0.40
for the HD and PP groups, respectively (i.e., a hazard ratio of 1.6).
Analyses were performed using SAS version 9.3 (SAS Institute, Inc.).
Results
Figure 1 summarizes the progress of patients who were screened and randomly assigned to
each group. Baseline demographic and clinical characteristics of the 145 PP and 145 HD
patients in the primary analysis are in Table 1. Patients were followed for a median of 488
days (25th–75th percentile: 225–645).
Dose
In the initial month of LAI treatment, which included doses on day 1 and day 8, the mean
dose of PP was 325 mg and of HD 94 mg. Subsequently the mean monthly dose of PP
ranged from 129–169 mg and the mean monthly dose of HD ranged from 67–83 mg.
Efficacy failure
In the primary analysis, there was no statistically significant difference in the rate of efficacy
failure (49 [33.8%] for PP vs. 47 [32.4%] for HD; site stratified log rank P=.90; site and
baseline PANSS adjusted hazard ratio 0.98, 95% CI 0.65–1.47) among patients randomized
to PP compared to HD (Figure 2). Results of all pre-planned sensitivity and supporting
analyses led to similar conclusions (Supplementary eTable 1). Reasons for efficacy failure
are in the Supplementary eTable 2. The most common reasons for efficacy failure noted by
the OAC were psychiatric hospitalization (44 (89.8%) of PP and 34 (72.3%) of HD events)
and clinician discontinuation of study medication due to inadequate therapeutic effect (34
(69.4%) PP and 28 (59.6%) HD events).
Secondary outcomes
On average, patients taking PP gained weight progressively over time while those on HD
lost weight. For example, at month 6 the least squares mean weight change for the PP group
was +2.17 kg (1.25 to 3.09) and for the HD group was −0.96 kg (−1.88 to −0.04). The test of
time-by-treatment interaction showed statistically significant treatment group differences
(p<0.0001) (Table 2). Seven patients on PP (4.8%) compared to 2 (1.4%) on HD
discontinued treatment due to weight gain.
There were no statistically significant differences between those treated with PP and HD in
mean change to the highest recorded levels of HbA1c, glucose, total cholesterol, LDL
cholesterol, and triglycerides; or in the lowest recorded levels of HDL cholesterol.
There were no statistically significant differences in changes in ratings of abnormal
involuntary movements as indicated by change from baseline score in the Abnormal
Involuntary Movement Scale (AIMS) global score (0.43 (0.31–0.55) for PP vs. 0.50 (0.38–
0.62) for HD; p=0.39). (Table 2) There was no statistically significant difference in the
incidence of probable TD (15 on PP (10.6%) and 21 on HD (15.4%), p=0.24). Patients
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taking HD experienced greater increases in Barnes Akathisia Scale (BAS) global scores
(0.45 (0.31–0.59) for PP vs. 0.73 (0.59–0.87) for HD; p=0.006). There were no statistically
significant difference in changes in ratings of Parkinsonism as measured by the mean
Simpson-Angus Extrapyramidal Scale (SAS) scale score (0.21 (0.16–0.27) for PP vs. 0.25
(0.20–0.30) for HD; p=0.34). Fewer patients taking PP than HD started a medication to treat
Parkinsonism (18 (15.8%) vs. 27 (29.3%), p=0.007) and akathisia (5 (3.6%) vs. 16 (11.0%),
p=0.03). Treatment discontinuations due to neurologic side effects according to clinician
judgment were as follows: 2 patients (1.4%) on HD and 1 (0.7%) on PP due to akathisia; 3
(2.0%) on HD compared to 1 (0.7%) on PP due to Parkinsonism, and 4 (2.7%) on HD
compared to 1 (0.7%) on PP due to tardive dyskinesia.
Mean serum prolactin levels increased for men and women treated with both PP and HD.
The mean highest prolactin level was higher for PP than HD for men (34.56 µg/L (1502.6
pmol/L) (SI unit conversion factor 43.478 to pmol/L) (29.75 to 39.37) vs. 15.41 µg/L (670
pmol/L)(10.73 to 20.08), p<0.001) and women (75.19 µg/L (3289.11 pmol/L)(63.03 to
87.36) vs. 26.84 µg/L (1166.95 pmol/L) (13.29 to 40.40), p<0.001). There were no
statistically significant differences in the proportions taking PP or HD who had a score on
the ASEX scale ≥ 19 indicating sexual dysfunction for men or women. There were no
significant differences in the incidence of gynecomastia or galactorrhea for men or women.
Overall, 68.0% of patients on PP compared to 59.9% of those on HD reported at least one
adverse effect rated as moderate or severe (Table 3). Among the individual items, 16.3% of
patients taking PP compared to 10.9% on HD developed sialorrhea. This is the only item
with a difference of 5% or more between the groups. Fifty-three (36.1%) of patients on PP
experienced a total of 69 serious adverse events (SAEs) compared to 45 (30.6%) on HD,
who experienced a total of 64 SAEs. One male participant in his sixties died of unknown
causes approximately six weeks after his last HD injection.
Decreases in PANSS total scores from baseline were similar for both groups at each time
point (See eFigure 1). For example, at month 6 the least squares mean PANSS change was
−6.87 (−8.79, −4.94) for PP and −6.40 (−8.32, −4.48) for HD. In addition, as seen in Figure
1, rates of treatment discontinuation due to any cause (104/147 [70.7%] for PP and 101/147
[68.7%] for HD) and due to unacceptable side effects (15/146 [10.2%] for PP and 14/147
[9.5%] for HD) were similar.
Discussion
This randomized clinical trial found no evidence that long-acting injectable PP was superior
to HD with respect to prevention of efficacy failure. However, based on the 95% confidence
limits for the event rates, the results cannot rule out a clinically meaningful difference
favoring one of the drugs.
Contrary to expectations, there was no statistically significant advantage for PP compared to
HD in ratings of the severity abnormal involuntary movements and Parkinsonism, or in the
incidence of TD. However, ratings of the severity of akathisia increased more for HD, and
more medications to manage akathisia and Parkinsonism were started for patients on HD,
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partially confirming that PP has a lower propensity to cause EPS than HD. The current study
was informed by studies from the 1980s that compared “standard” doses of typical LAI
antipsychotic medication with lower doses and found that patients could be successfully
maintained at these lower doses without relapse and without extrapyramidal toxicities.13–15
Similarly, the CATIE schizophrenia trial found that modest doses of typical oral
antipsychotic medication could be used effectively without excessive EPS.3 The modest
dose of haloperidol decanoate used here, about 75mg IM per month, is lower than the
equivalent oral dosage used in a trial that found an advantage of oral risperidone over oral
haloperidol.9 In that study, the average daily dose of haloperidol was 11.7±5.0 mg whereas
in this study, using a standard conversion from oral haloperidol to haloperidol decanoate of
10–15 times the daily dose, the corresponding daily dose is approximately 5.0–7.5 mg. The
modest dosing of haloperidol decanoate in this study is consistent with current
recommendations and may help to account for its better-than-expected comparative
tolerability. It was unexpected that the relapse rate was similar to that in the earlier study
comparing oral risperidone to oral haloperidol considering that the current study enrolled
people at increased risk of non-adherence and relapse. One reason may be that the outcome
in the oral trial, relapse, was somewhat broader than the definition of efficacy failure used
here. Another possible reason is that LAI antipsychotics are more useful than oral
antipsychotics in preventing relapse, but this question was not addressed in our study. The
higher doses of haloperidol in the prior study may have had a negative effect on its
tolerability and, consequentially, its effectiveness.
Early termination of the study’s follow-up period, which meant that patients enrolled during
the second year of the study were followed for at least one year but less than the planned
two years, had little effect on statistical power for the primary outcome because the risk of
efficacy failure during the second treatment year was low. However, the early termination
may have resulted in less reliable estimates of weight change at later time points.
The study did not include a comparison to an oral antipsychotic medication. At the time this
study was begun, two randomized clinical trials comparing oral and LAI antipsychotics were
underway. Neither of these studies found an advantage of LAI antipsychotics over oral
antipsychotics in reducing hospitalizations.16,17 The only of these to be published to date
had rates of hospitalization (45% for oral medication and 39% for LAI over two years) that
are similar to the current study.16 Nevertheless, the use of LAIs is supported by some
systematic reviews18,19 and expert panels20,21 for outpatients at increased risk of relapse. A
limitation is that the study did not include subjective measures of medication satisfaction or
global well-being. In addition, we have not addressed current cost differences for payers,
which may be substantial as PP is still on patent while HD is available as a generic.
Conclusion
Among adults with schizophrenia or schizoaffective disorder, treatment with paliperidone
palmitate compared with haloperidol decanoate did not result in a statistically significant
difference in efficacy failure, but the results do not rule out the possibility of a clinically
meaningful difference. The results are consistent with previous research that has not found
large differences in the effectiveness of newer and older antipsychotics.
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Figure 1. Participant enrollment and follow-up
*Patients were intended to stay in the study for 24 months or until the study was terminated
even if treatment was discontinued.
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Table 1









Age, mean (SD), y 43 (12.6) 45 (12.3)
Sex, No. (%)
  Male 106 (73.1) 110 (75.9)
  Female 39 (26.9) 35 (24.1)
Race, No. (%)
  White 56 (38.6) 54 (37.2)
  Black 83 (57.2) 83 (57.2)
  Othera 6 (4.1) 8 (5.5)
Spanish, Hispanic, or Latino ethnicity, No. (%) 6 (4.1) 8 (5.5)
Baseline clinical characteristics
In hospital, No. (%) 24 (16.6) 28 (19.3)
Weight, mean (SD), kg 90 (21.7) 90 (22.5)
BMI, mean (SD) 30 (7.4) 30 (7.3)
HbA1c (%) (SD) 5.9 (1.3) 5.6 (0.6)
Blood glucose (mg/dL) (SD) 104.0 (31.5) 94.6 (17.6)
Total Cholesterol (mg/dL) (SD) 179.7 (38.5) 181.5 (41.9)
LDL-cholesterol (mg/dL) (SD) 104.6 (35.1) 108.1 (33.0)
Triglycerides (mg/dL) (SD) 123.2 (85.4) 119.9 (80.5)
Prolactin (µg/L) men (SD) 17.4 (20.8) 17.8 (13.5)
Prolactin (µg/L) women (SD) 35.9 (35.2) 32.2 (38.5)
PANSS total score, mean (SD)b 73 (15.3) 70 (15.7)
CGI severity score, mean (SD)c 4.0 (0.8) 3.8 (0.9)
AIMS global severity score, median (range)d 0.0 (0–2) 0.0 (0–2)
SAS mean score, median (range)e 0.0 (0–1.5) 1.0 (0–1.5)
BAS global score, median (range)f 0.0 (0–3) 0.0 (0–3)
Psychiatric history, mean (SD)
Age at 1st treatment for any behavioral or emotional problem, years 23 (9.3) 24 (10.9)
Age at 1st antipsychotic medication, years 26 (9.0) 27 (10.1)
SCID diagnosis, No. (%)
Schizophrenia – lifetime 103 (71.0) 107 (73.8)
Schizoaffective disorder – lifetime 56 (38.6) 53 (36.6)
Major depression – past 5 years 36 (24.8) 40 (27.6)
Alcohol dependence – past 5 years 27 (18.6) 27 (18.6)
Alcohol abuse – past 5 years 42 (29.0) 43 (29.7)






























Drug dependence – past 5 years 33 (22.8) 36 (24.8)
Drug abuse – past 5 years 50 (34.5) 45 (31.0)
Antisocial personality disorder – past 5 years 17 (11.8) 16 (11.0)
Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BAS, Barnes akathisia scale; BMI, body mass index; CGI, Clinical Global
Impressions Scale; PANSS, Positive and Negative Syndrome Scale; SAS, Simpson-Angus Scale; SCID, Structured Clinical Interview for DSM-IV;
SD, standard deviation.
a
Race was self-reported. “Other” includes American Indian or Alaska Native, Asian, or Native Hawaiian or other Pacific Islander and two or more
races.
b
PANSS range is 30–210, with higher scores reflecting greater severity of psychopathology
b
CGI range is 1–7 with higher scores reflecting greater severity of illness
b
AIMS global score range is 0–4 higher scores reflecting greater severity of abnormal movements
b
SAS mean score range is 0–4 with higher scores reflecting greater severity of Parkinson’s symptoms
b
BAS global score range is 0–3 with higher scores reflecting greater severity of akathisia
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Table 2











Weight change from baseline
Least squares mean at month 6, mean (95% CI) 2.17 (1.25 to 3.09) −0.96 (−1.88 to −0.04) <.001a
Least squares mean at month 12, mean (95% CI) 3.46 (1.83 to 5.09) −1.93 (−3.56 to −0.31)
Least squares mean at month 18, mean (95% CI) 4.75 (2.36 to 7.14) −2.91 (−5.28 to −0.53)
Least squares mean at month 24, mean (95% CI) 6.04 (2.88 to 9.20) −3.88 (−7.02 to −0.73)
Ever gained ≥ 15 lbs from baseline, No. (%) 48 (33.1) 32 (22.4) 0.03b
Worst change from baseline in laboratory values
At least one laboratory assessment after first injection, No. of patients 129 126
HbA1c, Least squares mean (95% CI) 0.34 (0.17 to 0.52) 0.23 (0.06 to 0.41) 0.38c
Blood glucose, Least squares mean (95% CI) 21.13 (12.59 to 29.67) 20.96 (12.38 to 29.54) 0.98c
Total cholesterol, Least squares mean (95% CI) 12.42 (7.20 to 17.63) 16.82 (11.56 to 22.07) 0.25c
LDL, Least squares mean (95% CI) 11.70 (7.06 to 16.34) 13.49 (8.85 to 18.14) 0.59c
Triglycerides, Least squares mean (95% CI) 36.91 (22.40 to 51.43) 46.57 (31.93 to 61.21) 0.36c
HDL, Least squares mean (95% CI) −5.28 (−6.74 to −3.83) −4.52 (−5.98 to −3.05) 0.47c
Neurologic effects
AIMS global severity score
  Incidence of AIMS ≥ 2, No. (%) 28 (21.4) 30 (23.8) 0.57b
  Worst change from baseline, Least squares mean (95% CI) 0.43 (0.31 to 0.55) 0.50 (0.38 to 0.62) 0.39c
Barnes akathisia rating scale
  Incidence of BAS ≥ 3, No. (%) 4 (2.8) 15 (10.6) 0.006b
  Worst change from baseline, Least squares mean (95% CI) 0.45 (0.31 to 0.59) 0.73 (0.59 to 0.87) 0.006c
Simpson-Angus Extrapyramidal Scale (SAS)
  Incidence of SAS ≥ 1, No. (%) 109 (79.0) 101 (74.8) 0.45b
  Worst change from baseline, Least squares mean (95% CI) 0.21 (0.16 to 0.27) 0.25 (0.20 to 0.30) 0.34c
Serum prolactin levels
Among males only
  Highest level after baseline, Least squares mean (95% CI) 34.56 (29.75 to 39.37) 15.41 (10.73 to 20.08) <.001d
  Worst ASEX after baseline, Least squares mean (95% CI)f 17.68 (16.36 to 19.00) 17.95 (16.66 to 19.25) 0.77d
  ASEX score ≥ 19, No. (%) 34 (37.8) 37 (39.4) 0.72b
  Incidence of gynecomastia or galactorrhea, No. (%) 5 (4.7) 3 (2.8) 0.46e
Among females only
  Highest level after baseline, Least squares mean (95% CI) 75.19 (63.03 to 87.36) 26.84 (13.29 to 40.40) <.001d

































  Worst ASEX after baseline, Least squares mean (95% CI)f 23.41 (21.01 to 25.80) 22.83 (20.12 to 25.54) 0.75d
  ASEX score ≥ 19, No. (%) 24 (72.7) 19 (73.1) 0.88b
  Incidence of gynecomastia or galactorrheag, No. (%) 10 (38.5) 5 (29.4) 0.13b
Abbreviations: AIMS, Abnormal Involuntary Movement Scale; ASEX, Arizona Sexual Side Effects; BAS, Barnes akathisia rating scale; CI,
confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein; SAS, Simpson-Angus Scale.
a
P Value is from test of time by treatment interaction.
b
P Value for the comparison of binary outcomes is from a Cochran-Mantel-Haenszel (CMH) test stratified by grouped-site.
c
P Value for overall comparison between treatment groups obtained from analysis of covariance adjusting for baseline value and pooled site. The
least squares mean and standard error are from the corresponding analysis of covariance model.
d
P Value for overall comparison between treatment groups obtained from analysis of variance adjusting for pooled site. The least squares mean
and standard error are from the corresponding analysis of variance model.
e
P Value is from Barndard’s exact test, due to low event counts in males.
f
Range of the Arizona Sexual Experiences Scale (ASEX) is 6–30 with higher scores representing worse sexual functioning.
g
Incidence among premenopausal females only.
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Table 3








Serious Adverse events, No. (%)
Any serious adverse event 53 (36.1) 45 (30.6)
Suicidal or homicidal ideation 23 (15.6) 21 (14.3)
Adverse events, No. (%)
Any moderate or severe adverse event from systematic inquiry 100 (68.0) 88 (59.9)
  Insomnia 49 (33.3) 54 (36.7)
  Sleepiness 41 (27.9) 44 (29.9)
  Dry mouth 40 (27.2) 34 (23.1)
  Increased appetite 33 (22.4) 26 (17.7)
  Hypersomnia 24 (16.3) 20 (13.6)
  Constipation 21 (14.3) 20 (13.6)
  Sialorrhea 24 (16.3) 16 (10.9)
  Orthostatic faintness 14 (9.5) 12 (8.2)
  Incontinence/nocturia 13 (8.8) 8 (5.4)
  Menstrual irregularities 12 (8.2) 5 (3.4)
  Urinary hesitancy 7 (4.8) 9 (6.1)
  Gynecomastia/galactorrhea 4 (2.7) 5 (3.4)
JAMA. Author manuscript; available in PMC 2014 November 21.
